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There is a gap between the medical and economic weight of acute otitis media and the imprecise knowledge and 
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INTRODUCTION 
There is a surprising gap between the medical and eco- 
nomic weight of acute otitis media (AOM) in advanced 
countries and the imprecise knowledge and irrational 
attitude of prescribers. Precise criteria for diagnosing 
the condition are lacking and the optimal treatment is 
uncertain. The multiple variables that influence doctors’ 
choices of treatment are unknown and the wide 
variations need to be elucidated and analyzed. In such 
a context, a rational choice would be the most effective 
protocol [l-31. The prior requirement for a reliable 
cost-effectiveness analysis is a precise definition of the 
disease and of treatment efficacy [4]. 
DEFINITIONS FOR A RELIABLE COST-EFFECTIVENESS 
ANALYSIS 
‘Could God make a better world than ours ? 
To answer the question, firstly we have to know 
what we mean by “world”; 
secondly what we mean by “better”; 
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thirdly, we shall have to answer the question’ 
(William of Ockham 1290-1349) 
The diagnosis of AOM relies on the presence of both 
acute symptoms, earache, fever, irritability, respiratory 
infection symptoms, restless sleep, anorexia, vomiting 
or diarrhea-ear pulling is not a reliable sign of 
AOM-and otoscopic signs, distinct redness and out- 
ward bulging, or perforation, or reduced mobility of 
the eardrum with pneumo-otoscopy [2,5]. At least 
one of the acute symptoms and one of the pneumo- 
or otoscopic findings are required for the diagnosis. 
Redness of the tympanic membrane is an inconsistent 
finding: in most patients, the main diagnostic color is 
adjudged to be yellow or ‘cloudy’. The tympanic 
membrane may look normal although the mobility is 
decreased. Assessing the movement of the eardrum by 
pneumatic otoscopy requires much experience. Pneu- 
matic otoscopy does not require additional expensive 
equipment, and correlations with tympanometry are 
good. There are no reports, however, of doctors in 
primary care using it to assess AOM, and the tympanic 
membranes of young infants are less compliant than 
those of older children. Fifty per cent of AOM episodes 
in infants less than 1 year of age may be asymptomatic 
and discovered by systematic otoscopic examination 
at  well-child visit. The appearance of the tympanic 
membrane is highly variable and often results in a 
subjective diagnosis of AOM. This is the weak point 
of the diagnosis. When a tympanostomy tube or 
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perforation is present with otorrhea, it may be classified 
as AOM when accompanied by acute symptoms [S]. 
The criterion of efficacy is the resolution of systemic 
and otoscopic signs. The  primary endpoint is the 
clinical response. Clinical success at the primary control 
is defined by the absence of all presenting signs and 
symptoms as reported by the parent at the evaluation 
point closest to 7-14 days. Clinical failure is defined 
as persistent fever, otalgia, otorrhea or continued 
irritability deemed significant enough to warrant 
discontinuation of the initial medication. 
Surgical puncture of the tympanic membrane 
contributes to diagnostic certainty but it is unlikely to 
be popular among doctors in primary care or their 
patients. As long as the culture of middle ear exudate 
has been made and has shown the presence of bacteria, 
bacteriologic success is defined by a sterile middle ear 
fluid culture after 3-6 days of therapy. Bacteriologic 
failure is defined as isolation of a pathogen from middle 
ear exudate at this time. Tympanocentesis and/or 
myringotomy is performed primarily to relieve the 
symptoms of the child. It has not been found to affect 
the course of AOM [6]. 
The secondary endpoint is related to the absence 
or presence of middle ear effusion (MEE) after resolu- 
tion of the acute infection. Successful secondary control 
is defined as the absence of MEE in both ears at the 
evaluation point closest to 30 days after therapy was 
started. Persistence of MEE in one or both ears is 
considered a secondary endpoint failure. A cut-off 
point of 30 days is selected because many practitioners 
would consider retreatment with additional antibiotics 
for effusion persisting at that time, although most of 
these effusions would probably resolve spontaneously 
without further treatment [7]. 
Among 13 studies providing results of tympano- 
centesis at the beginning of clinical manifestations of 
AOM, Rosenfeld et a1 [8] reported that 23-47% (mean 
33%) of middle ear fluids were sterile or did not contain 
any pathogenic bacteria. The percentage of fluids with 
0-lactamase-producing pathogens ranged from 3% 
to 19%. In untreated patients with a bacterial AOM, 
the expected rate of bacteriologic success has been 
estimated to be 27% 171. Without any antibiotic 
prescription, the spontaneous clinical success rate on 
the primary control has been reported as 65%. 
Antibacterial therapy increases the clinical success 
rate. Rosenfeld et a1 reported the following clinical 
success rates on the first endpoint after 5-7 days [8]: 
controls 69.8% t17.396 
standard-spectrum antibiotics 76.6% ? 16.7% 
extended-spectrum antibiotics 85.9% ?12.8% 
Comparative efficacy was measured by the rate dif- 
ference (RD) obtained by subtracting the control group 
success rate from the treatment group success rate. R D  
is equivalent to the absolute risk reduction. The  mean 
primary control RDs were + 13.1%?5.6% for anti- 
microbial versus control groups, and 1.3% ? 9.5% for 
extended-spectrum versus standard spectrum drugs. 
For the secondary endpoint, Rosenfeld et al. [8] 
reported the following control rates-delayed resolu- 
tion of MEE: 
controls 65% 
standard-spectrum antibiotics 60.0%+ 15.6% 
extended-spectrum antibiotics 59.9‘%, ? 19.6% 
For the secondary control of MEE, no significant 
association was found between the secondary clinical 
success rate and tympanocentesis, or antibacterial 
spectrum, or conipliance check; no significant differ- 
ence was found for amoxicillin-clavulanate versus 
cefaclor or for cefaclor versus cefixim. Aminopenicillin 
showed significant homogeneous benefits versus 
placebo or no drug as evidenced by a 12.9% increase in 
the rate of primary control (95% CI, 6.8-79.096). For 
extended- spectrum versus standard-spectrum drugs, 
the mean primary control comparisons were 
1.3% f 9.5% [S]. Antibacterial spectrum, therefore, was 
not significantly associated with clinical primary 
control rates. 
Data correlating eradication of the organism with 
the clinical course ofAOM suggest that about one third 
of patients require antibiotic activity for the resolution 
of clinical signs and symptoms. In the other two thirds 
of treated children, symptoms resolve without eradica- 
tion of the middle ear pathogen. Unfortunately, it is not 
possible to identifi clinical criteria that distinguish the 
patients who require antibiotic therapy to eradicate the 
pathogen from those who do not [9]. 
Among 448 children with AOM, Marchant et al. 
documented a bacterial AOM for 293 patients (65.4%), 
approximately two thirds of the patients [7]. Among the 
293 patients with a documented bacterial AOM, an 
antibacterial effect (bacterial success rate) has been 
observed for 253/293=0.86 or 86%, and a clinical 
success has been observed for 261 patients: clinical 
success rate was 261 /293=0.89 or 89% (Table 1). 
Clinical success rate is significantly associated with 
antibacterial activity (Chi’ test= 33.64, p<0.001), but 
the correlation between, respectively, bacterial and 
clinical success rates is poor, as indicated by the 
coefficient Phi @, interpretable as a correlation 
coefficient: @=.\i (X’/N) = 0.34. Therefore, clinical 
success rate is estimated as depending on antibacterial 
activity for (0.34)’= 0.116, approximately 10%. 
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Bact. success 
Bact. failure 
Table 1 Clinical success rates observed in 448 patients prescribed empirical antibiotic treatment with amoxicillin, according 
to the presence or absence of identified bacterial pathogen in the middle ear exudate-from Marchant et al. [7] 
236 (0.80) 17 (0.06) 253 (0.86) 
25 (0.09) 15 (0.05) 40 (0.l4) 
Bacterial otitis media (65.4 01.) Non-bacterial otitis media (34.6 oh) 
385 (0.86) 63 ( 0.14) 
Clinical Clinical 
success failure total 
448 (1 .oo) 
Clinical Clinical total 
success failure 
261 (0.89) 32 (0.1 1) 293 (1 .OO) 
According to the data of Table 1, the estimated 
predictive value or probability of clinical success given 
antibacterial activity (bacterial success) was 236/253= 
0.93; the probability of the same clinical success despite 
bacterial failure was 25/40=0.63. The relative benefit 
of the antibiotic prescription is 0.93/0.63= 1.48 with 
an odds ra t io~8.33  (95% confidence interval 3.7-18.7), 
significantly greater than one. 
The absolute clinical benefit or effect attributable to 
the antibacterial activity is estimated by the difference 
0.93 -0.63=0.30. The number of patients with 
documented bacterial otitis who must be treated to 
prevent one adverse effect or to obtain the benefit for 
one child relying on the antibacterial drug is the 
reciprocal of the absolute attributable effect: 1 /0.30 = 
3.3, say approximately 4 patients. The number for one 
tells clinicians and parents the amount of effort that 
must be expended-e.g. how many patients have to be 
treated with an antimicrobial agent to increase the rate 
of primary control for a single child or to prevent one 
unfavorable event. 
Among the 155 children with a non-bacterial 
AOM (Table l), the observed clinical success rate was 
124/155=0.80. Among all the patients with AOM, the 
overall clinical success rate was 385/448=0.86 or 86% 
and clinical success rate that was not dependent on 
antibacterial activity was: 
25 + 124 
40 + 155 
= 0.76. 
The net clinical benefit of antibacterial activity is the 
difference 0.80 - 0 .76~0 .04  indicating that 1 /0.04= 25 
children should be treated to obtain an average increase 
of one clinical success. 
Empirical antibiotic prescription significantly in- 
creases the clinical success rate [8].  
Clinical success rates may be used to calculate the 
‘expected’ clinical efficacy for drugs with varying levels 
of bacteriologic efficacy. Among patients with a 
bacterial AOM, clinical improvement occurs in 90% of 
those with bacterial pathogens eliminated from the 
middle ear (bacteriologic success) and in only 60% of 
those with bacteria still present (bacteriologic failure). 
If the bacterial success related to the antibiotic drug is 
assumed to occur with a probability ‘b’, and bacterial 
failure with a probability (1 - b), the resulting clinical 
success rate could be illustrated by the probability tree 
in Figure 1. 
Folding back the probability tree from right to left, 
gives an average clinical success rate of: 
[0.90 x b+0.60x (l-b)]0.65+0.35 x 0.80=0.67+0.20~ b
Hence, clinical success rate is a linear function 
of the antibacterial activity of the antibiotic drug, 
illustrated by the linear curve in Figure 2 where the 
antibacterial activity varies from 0 to 1. For an agent 
with an antibacterial effect of 1, clinical success rate will 
be 0.87. If bacterial activity is 0.84, the clinical success 
rate is also 0.84. Bacteriologic success and clinical 
success rates are equal when the antibacterial activity of 
the drug is about 0.84. When the bacteriologic efficacy 
is less than 0.84, clinical outcome overestimates bacterio- 
logic efficacy; beyond this level, it underestimates anti- 
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Figure 1 Probability tree of clinical success rate observed in relation to an antibacterial effect of the prescribed antibiotic 
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Figure 2 Regression line of clinical efficacy on antibacterial activity of antibiotic treatment. Along the identity broken line, 
the clinical success rate is equal to the antibacterial activity or bacterial success rate. 
bacterial activity. A drug with no antibacterial effect- 
given that the expected rate of bacteriologic success in 
untreated patients is 0.27-would give a calculated 
clinical efficacy of 0.61 for all AOM. 
Marchant et a1 underline the important effects 
of the discrepancy between bacteriologic and clinical 
outcomes for the ability to assess the comparative 
efficacies of antibacterial agents. A drug that eliminates 
bacteria from the middle ear in 100% of cases will not 
have 100% clinical response because of other factors, 
such as concurrent viral infection. A drug with a 
minimal antibacterial activity will appear to be almost 
as effective as a highly efficacious drug; this effect 
appears to predominate until bacteriologic efficacy 
reaches 85-90% [7]. Therefore most studies are unable 
to identify a higher rate of clinical success related to a 
more powerful antibacterial therapy (Figure 2). Sample 
sizes required to show a difference at a significance level 
of 0.05 and a power of 0.90, between a drug with 30% 
(minimal) bacteriologic efficacy and a drug with 90% 
efficacy, would need about 30 subjects to assess the 
bacteriologic outcome, more than 200 for clinical 
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efficacy in bacterial AOM, and more than 500 for 
clinical efficacy in all types of AOM [7]. 
Drugs with substantially better antibacterial activity 
have only slightly better effects in terms of improved 
symptomatic outcome than a less active drug has. 
However, AOM is such a common disease that small 
differences may be important because of the large 
numbers of children involved. If a drug with a bacterio- 
logic cure rate which is 20% less than that of alternatives 
is prescribed for 1 million children, 40 000 children 
will continue to have symptoms who would otherwise 
have had relief. Since many new drugs may be more 
expensive, and some antibacterial agents are associated 
with adverse reactions, it is worthwhile knowing 
whether these agents are also substantialy more effi- 
cacious [7]. 
The timing of follow-up visits depends on the 
child's response to therapy [9]. Parental judgment and 
observation will accurately identify children whose 
AOM has resolved. Children who become asymp- 
tomatic should have a follow-up visit 3-6 weeks after 
treatment begins. When symptoms of AOM continue 
beyond 48 h or recur before the next scheduled visit, 
children should be reassessed. 
RISK FACTORS AND UNFAVORABLE EVENTS 
Follow-up of children with risk factors for treatment 
failure should take place 2-3 weeks after the initiation 
of therapy. Many risk factors of complicated or 
recurrent AOM have been identified: orofacial dys- 
morphias, such as cleft palate or submucosal cleft palate, 
trisomy 21; congenital or acquired immunodeficiencies; 
adenoid hypertrophy or pharyngeal tumors. The most 
commonly encountered risk factors are: age less than 
15 months-with a considerable morbidity in infants 
with otitis beginning before the age of 2 months-a 
history of recurrent AOM in the child or a sibling, 
nursery day care, number of siblings and age of the 
child, a convincing history of atopy, bottle feeding, 
parent smoking and antibiotic treatment of AOM 
within the previous month. Parental smoking and 
bottle feeding appear to have only a moderate impact. 
However, the risk of a new episode of AOM is 
quadrupled within 3 months of the most recent 
episode, and the risk is still elevated after 3 months have 
passed, compared with a child without any previous 
episodes. These factors are closely interrelated and 
frequently competing, causing a confounding effect. 
For instance, nursery day care generates a marked 
change in the average risk, but this change depends 
on the situation of the child, altering the risk more 
dramatically if the child has no siblings and the parents 
do not smoke. Given that a child had already had an 
AOM episode, the risk appears to be independent of 
the number of siblings. Among the alterable risk 
factors, the strongest effect is associated with day-care 
arrangement, and it appears to be slightly greater for 
the first than for the subsequent episodes [lo]. Hence, 
in order to be able to assess the risk in the case of 
an individual child, all risk factor values must be 
considered simultaneously. 
The main and indisputable risk factor that will be 
taken into account is an AOM episode in the preceding 
3 months. 
Persistent middle ear efusion (MEE). MEE is defined 
by an asymptomatic middle ear effusion found by 
otoscopic examination, with presence of a visible 
air-fluid level or a reduced mobility of the tympanic 
membrane by pneumatic otoscopy or tympanocentesis 
up to 16 weeks after the acute episode. Decreased 
tympanic mobility to positive external ear canal pressure 
only, indicative of negative middle ear pressure, is not 
considered to indicate MEE [ l  11. 
In about 20-40% of cases in infants less than 
2 years of age, a middle ear effusion persists for 4-6 
weeks after treating AOM and after resolution of 
clinical symptomatology, defining persistent middle ear 
effusion (MEE) or otitis media with effusion (OME). 
Ten per cent have an effusion that is still present 3 
months after the acute episode, defining chronic otitis 
media with residual effusion where a middle ear effusion 
continues for 2 3 months. 
The spontaneous resolution rates for effusion 
present for longer than 6 weeks despite previous 
antimicrobial therapy vary from 6% to 57% during the 
subsequent 1-3 months [12]. Resolution of persistent 
middle ear effusion is delayed in young infants and in 
those whose parents smoke. The type of antimicrobial 
therapy does not affect the duration of MEE and nor 
did use of antihistamines or decongestants. 
Resolution of middle ear exudate is considered an 
important measure of outcome after treatment of otitis 
media because of the effect of middle ear fluid on 
hearing. Persisting effusion is associated with a mild to 
moderate conductive hearing impairment of 20 dl3 or 
more. The conductive hearing loss may have a major 
impact on the quality of life [13]. The benefit of rapid 
restoration of hearing is a critical issue. No studies have 
directly addressed the question of whether restoration 
of hearing with ventilating tubes promotes language 
development. Conservative treatment associates anti- 
biotic with or without anti-inflammatory drugs 
or corticosteroids. Children whose bilateral MEEs 
persist for 12 weeks despite medical management 
should be referred for ventilating tubes and/or 
adenoidectomy [12]. 
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Unresponsive AO& is characterized by both clinical 
symptoms and otoscopic findings of membrane inflam- 
mation that persist after 48 h of antibiotic therapy. This 
condition occurs in about 10% of children who are 
initially treated with a 10-day course of antibiotics. 
Unresponsive AOM occurs more frequently when 
antibiotic therapy fails to eradicate pathogens than 
when the pathogens are eradicated. Unresponsive 
AOM indicates tympanocentesis or myringotomy to 
identify bacterial pathogens: organisms resistant to the 
initial therapy can be identified in one fifth of middle 
ear aspirates. Unresponsive AOM may be treated by 
an expended-spectrum antibiotic, such as amoxicillin- 
clavulanate or cefaclor [9]. 
Cases in which otitis reappears after a symptom- 
free period of at least 2 weeks are considered as 
recurrences. Recurrent AOM can be considered to exist 
when three new episodes of the condition occur within 
a 6-month period. A meta-analysis of nine randomized 
controlled trials compared the rates of occurrence of 
AOM in patients who received antibiotic prophylaxis 
and in a placebo group. Antibiotic prophylaxis reduced 
the relative frequency of new episodes of AOM by 
44%; the mean absolute reduction of risk is 0.11 (95% 
CI, 0.03 to 0.19) [S]. 
SuppuYative complications. Those who favor antibiotic 
treatment attribute the rapid decline in the incidence 
of mastoiditis and other complications of otitis in 
the late 1940s and 1950s to the introduction and 
widespread use of antibiotic therapy. According to a 
1954 publication, the frequency of clinical mastoiditis 
was 17.3% (44 of 254) in the patients who were not 
treated, 1.5% (4 of 267) in the patients receiving 
sulfonamide, and 0% in the 333 patients receiving oral 
penicillin, in the 275 receiving intramuscular penicillin, 
and in the 236 receiving oral penicillin and sulfonamide 
[9]. In The Netherlands, this decrease of suppurative 
complications was initially attributed to treatment with 
paracentesis. It is probably not the result of treatment 
with either antibiotics or paracentesis; it cannot be an 
argument for the routine antibiotic treatment of all 
cases of AOM. Since the 1980s, the use of paracentesis 
and antibiotics has been virtually abandoned in The 
Netherlands. According to van Buchem, watchful 
waiting is the approach of choice for all patients older 
than 1 year. This approach has been tested over a period 
of 17 months in 5000 children, aged 2--12 years, with 
AOM. Mastoiditis developed in only two children 
(0.04% or 4/10 000) and both responded well to 
antibiotic therapy [14]. 
The following conclusions emerge from the pre- 
ceding analysis: 
1. A bacterial infection is identified in two thirds 
of middle ear fluids of AOM in childhood. The 
correlation of a bacterial eradication in middle ear 
fluid with clinical cure is statistically significant, 
although on a weak level. 
At the first endpoint on days 5-7, spontaneous cure 
rate for all AOM is about 85%-six out of seven 
patients. A clinical cure rate of 90% may be expected 
for the initial antibiotic treatment with a standard- 
spectrum antibiotic, such as amoxicillin for 5-7 
days. The incremental efficacy provided by an 
extended-spectrum and more costly antibacterial 
prescription is not clinically significant. So, the first- 
line antibacterial prescription still relies on oral 
amoxicillin for 5-7 days. 
Persisting middle ear exudate occurs in 10% of 
cases. Spontaneous resolution of middle ear exudate 
occurs in 65% of cases. Clinical failure and persisting 
middle ear exudate may be treated with P-lactamase 
stable antibiotic treatment for 7-1 0 days. However, 
cure rate is not significantly influenced by the 
antibiotic regimen. 
These conclusions apply mostly to children more 
than 2 years of age. Bacterial infection risks in 
infants less than 2 years old justify a systematic initial 
treatment with antibiotics. 
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